Fewer injections could help you
embrace life’s magical moments

ILUVIEN® 0.19 mg is the only prescription medication for DME that delivers up to 36 months of continuous treatment with a single injection for appropriate patients.

What's in it for you?

Fewer eye appointments that require injection over time

An effective treatment option based on clinical studies

Sustained vision with continuous treatment

The opportunity to enjoy those amazing moments in life

ILUVIEN may be an option for you if you have DME and have received a course of cortcosteroids and did not have a significant increase in eye pressure.

Individual results may vary. Talk to your eye doctor about the appropriate treatment for you.

Learn about the possibility of sustained
vision with continuous DME treatment

Sign up now to receive exclusive content, including disease education support, financial assistance options, and so much more.

Sign me up
Hovering firefly

Talk to your eye doctor about DME and ILUVIEN

Here are some questions you can ask your eye doctor to help get the conversation started:

"How does my diabetes affect DME?"

"What are the limitations of having DME?"

"Are there steps I can take to help slow the progression of DME?"

See and Print More Questions


AccessPlus Logo

AccessPlus is here for you

The ILUVIEN AccessPlus Program provides the financial support you may need so you can focus on life's incredible moments, not on the cost of your DME treatment.

What does AccessPlus include?

Financial Assistance Services

Assisting with out-of-pocket costs*

ILUVIEN CoPay Program

Copay assistance for eligible patients

Assistance Program

Providing FREE treatment for uninsured patients

Independent Financial
Assistance Foundations

Helping patients insured by a government payer

*Limitations apply. Payment assistance programs are for qualified insured and uninsurred patients who are eligible for ILUVIEN.

Limitations apply. The ILUVIEN CoPay Program does not apply to patient cost sharing for the injection procedure, diagnostic tests, or other costs associated with ILUVIEN treatment.

Limitations apply. The ILUVIEN Patient Assistance Program does not provide assistance for the injection procedure, diagnostic tests, or other costs associated with the administration of ILUVIEN.

Get access to exclusive content

Sign up today for disease education support, AccessPlus financial information, and more.

Sign up now
Indication and Important Safety Information


ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

Important Safety Information

  • Do not use ILUVIEN if you have or think you might have an infection in or around the eye.
  • ILUVIEN should not be used if you have advanced glaucoma.
  • You should not use ILUVIEN if you are allergic to any ingredients of ILUVIEN.
  • Injections into the vitreous in the eye are associated with a serious eye infection (endophthalmitis), eye inflammation, increased eye pressure, glaucoma, and retinal detachments. Your eye doctor should monitor you regularly after the injection.
  • Use of corticosteroids including ILUVIEN may produce cataracts (ILUVIEN 82%; sham 50%), increased eye pressure (ILUVIEN 34%; sham 10%), glaucoma, and may increase secondary eye infections due to bacteria, fungi, or viruses. Let your doctor know if you have a history of herpes viral infections of the eye.
  • If the posterior capsule of the lens of your eye is missing or torn the ILUVIEN implant may move to the front chamber of the eye.
  • The most common side effects reported in patients with diabetic macular edema who were treated with ILUVIEN include cataracts (ILUVIEN 82%; sham 50%) and increased eye pressure (ILUVIEN 34%; sham 10%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.